Pro-Dex (NASDAQ:PDEX) Shares Pass Below 200 Day Moving Average - Should You Sell?

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $46.51 and traded as low as $39.61. Pro-Dex shares last traded at $40.27, with a volume of 136,676 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Pro-Dex from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th.

Pro-Dex Stock Performance

The stock has a market capitalization of $140.61 million, a PE ratio of 21.45 and a beta of 0.37. The business's 50-day moving average is $53.36 and its two-hundred day moving average is $46.86. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.51. The business had revenue of $17.41 million during the quarter, compared to analysts' expectations of $17.70 million. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, equities research analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Raymond E. Cabillot sold 3,096 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $50.13, for a total value of $155,202.48. Following the transaction, the director now directly owns 279,787 shares of the company's stock, valued at approximately $14,025,722.31. This trade represents a 1.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 21,383 shares of company stock valued at $1,031,182 over the last three months. Company insiders own 47.50% of the company's stock.

Hedge Funds Weigh In On Pro-Dex

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in shares of Pro-Dex during the first quarter worth $170,000. Bank of New York Mellon Corp acquired a new stake in Pro-Dex in the 4th quarter worth about $202,000. Trexquant Investment LP acquired a new stake in Pro-Dex in the 4th quarter worth about $252,000. Integrated Quantitative Investments LLC acquired a new position in shares of Pro-Dex in the 4th quarter valued at approximately $254,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Pro-Dex during the 4th quarter worth approximately $255,000. Institutional investors and hedge funds own 15.28% of the company's stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.